Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

Inclusion criteria:

* Male vaccinated with at least one dose of GARDASIL™ after the October 2009 FDA date of first licensure of GARDASIL™ for males

Exclusion criteria all cohorts:

* Female
* Male vaccinated prior to the October 2009 FDA date of first licensure of GARDASIL™ for males
* Male who received all doses of GARDASIL™ outside of the health plan

Exclusion criteria, Regimen Completers cohort:

* Male \< 9 and \> 26 years of age at first dose
* Male not part of health plan at each dose
* 3-dose vaccination regimen given over a period \> 12 months
* Less than 28-day interval between first and second dose
* Less than 12 weeks between the second and third dose
* Less than 24 weeks between first and third dose

Exclusion criteria, Autoimmune cohort:

\- Male with less than 12 months of health plan membership prior to first dose of GARDASIL™